Fig. 2: B cells are enriched after STING agonist treatment in orthotopic HCA-1 and RIL-175 murine HCCs.

a Overall survival of HCC-bearing mice after weekly administration of STING agonist treatment or control for two doses. Log-rank test, n = 13/group. b Flow cytometry analysis of intratumor CD19⁺ B cells in both groups. The gating panel is shown in Supplementary Fig. 2e. c Comparison of the proportion of CD19⁺ cells in CD45⁺ cells from the HCA-1 orthotopic HCC tumors between STING agonist-treated and control groups (n = 4/group). P-value from two-sided Mann–Whitney U test. d Enrichment score calculated by xCell of subtypes of B cells between STING agonist-treated and control groups (n = 3/group). Th box plot shows the median (center line), interquartile range (box bounds), and whiskers extending to the minimum and maximum values within 1.5× the interquartile range. P-value from two-sided Mann–Whitney test. e Representative immunofluorescence (IF) for the B-cell markers CD19 and B220 among the two groups (scale bar, 20 μm). f Comparison of the percentage of CD19⁺B220⁺ cells of tumor samples collected from HCA-1 murine HCC, showing significantly higher infiltration of B cells after STING agonist treatment (P-value from two-sided Mann–Whitney U test, n = 15/group). g Representative IF results for tissues collected from control and STING-agonism-treated mice on days 5 and 12. Scale bar = 1 mm on the left column, other scale bar = 50 μm. Tumor regions were delineated by yellow lines. h Statistical comparison of the number of TLS-like structures per mm². P-value from one-way ANOVA with Tukey’s test, n = 8/group on day 5 and n = 9/group on day 12. Data of (c, f, and h) are presented as mean ± SD. Source data are provided as a Source Data file.